Press Releases
Dec 8, 2023

CRESEMBA is the only azole antifungal therapy approved for pediatric patients as young as one affected by these serious, potentially life-threatening infections Approval based on results of two...

Nov 30, 2023

– Results of pivotal confirmatory trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall survival and progression-free survival vs standard platinum...

Nov 29, 2023

Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity of moderate to severe vasomotor...


Oct 10, 2023

Astellas ranked in Seramount’s 2023 “100 Best Companies” list for the ninth consecutive year This year, Astellas once again was named as a top company for working parents on Seramount’s...

Oct 10, 2023

Astellas was once again ranked in Seramount’s 2023 list of 100 Best Companies confirming our commitment to creating a supportive workplace for working parents. This year, Astellas is proud to...

Oct 2, 2023

Astellas reflects on the importance of engagement, diversity, equity and inclusion in fostering a people-centric culture. Astellas is proud to celebrate Global Diversity Awareness Month this...


Stay Connected

Get only the email alerts you want.


Media Contacts


For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.


Astellas on Twitter
Download Fact Sheet
Explore U.S. Products